Sue, Author at InSphero

Sue

May 1, 2020

Experimental Design Considerations for
NASH Drug Screening

An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
September 23, 2019

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
June 18, 2018

Why we need better preclinical models for NASH Drug Discovery

In honor of the inaugural International NASH Day, an initiative to raise awareness of nonalcoholic steatohepatitis (NASH), I thought it would be appropriate to reflect on the current status of […]